Navigation Links
Personalizing cancer: Creating biomarkers from tumor DNA
Date:2/18/2010

Researchers have developed a new technique for tracking cancer by identifying personalized biomarkers from tumor DNA, reports a new study in the 24 February 2010 issue of the journal Science Translational Medicine, published by AAAS, the nonprofit science society. The findings show that next-generation sequencing technology is poised become an important tool in the new era of personalized management of cancer patients.

"There is currently no test for cancer patients that provides personalized biomarkers for clinical management of disease, and we feel that this is an important step in bringing new genome sequencing technologies to personalized patient care," said senior author Victor Velculescu, associate professor of oncology and Co-Director of the Cancer Biology Program at Johns Hopkins.

Keeping cancer cells under control requires the ability to monitor residual and recurrent tumors in order to assess whether or not treatment is working. Based on discovering cancer-related changes in DNA, the Personalized Analysis of Rearranged Ends or PARE approach provides a highly accurate and specific way to monitor tumors, by searching for the genetic bread-crumb trail left by lingering cancer cells after surgery or during drug therapy.

"We believe that this is one of the first applications of new genome sequencing technologies that could be useful for cancer patients," said Velculescu.

A nearly universal feature of human cancer is the widespread rearrangement of DNA. Yet historically, it has been difficult to accurately map such changes in individual tumors. Now, Velculescu and a team of colleagues from Johns Hopkins University and Life Technologies Corporation have used PARE to identify a handful of rearranged DNA sequences in four colorectal and two breast tumors.

Since these rearranged sequences are not present in normal DNA (only in tumor DNA), the researchers were able to create personalized biomarkers or "red flags" based on these unique sequences.

They used the biomarkers to hunt down tiny amounts of tumor DNA meshed within large quantities of normal DNA in blood and other bodily fluid samples--as could easily be done following surgical removal of tumors or other therapies.

"PARE uses genetic characteristics unique to the tumor to monitor disease progression. By exploiting rearrangements specific to the patient's tumor, we have developed a personalized approach for detection of residual disease," said co-author Rebecca Leary, graduate student at the Johns Hopkins Kimmel Cancer Center.

Granted, PARE is expensivea tough barrier to cross in the shift towards broad clinical application. Nonetheless, this approach may profoundly alter how the effectiveness of cancer treatments like radiation, chemotherapy, and surgery are assessed in individual patients.

"As PARE becomes affordable, it will be a helpful addition for physicians to tailor patient care and may become a useful supplement to traditional monitoring by imaging or other approaches," said Leary.


'/>"/>

Contact: Natasha Pinol
npinol@aaas.org
202-326-7088
American Association for the Advancement of Science
Source:Eurekalert

Related medicine news :

1. Research increases possibilities of personalizing treatment of infant osteosarcoma
2. Personalizing medicine: New research shows potential of targeted therapies for cancer
3. Lung Cancer: Large Impact, Little Funding
4. Exposing the Double Standard of the Forgotten Cancer: Biggest Cancer Killer for Women and Men, Lung Cancer, Receives Least Research Funds
5. NCCN Emphasizes Tailored Treatment in Discovery Health Channel Program Metastatic Breast Cancer: Individualizing Treatment
6. Cholesterol and Cancer: Answers and Some New Questions
7. Exercise May Prevent Prostate Cancer: Study
8. Pancreatic cancer: Researchers find drug that reverses resistance to chemotherapy
9. HPV vaccine could prevent breast cancer: Australian research
10. Breast cancer: Risk increases for smokers and overweight women
11. Prostate cancer: Racial disparity gap narrows, men diagnosed at younger age
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... ... EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This conference ... estimated 5000 perioperative nurses in attendance to study the latest evidence-based recommendations ...
(Date:2/6/2016)... ... ... Shark Finds and Kevin Harrington, along with the Product Managers ... Belly Bands. , Having a dog is great—except when it wets every couch, bed, ... works, get Belly Bands, the easiest way to stop dogs from wetting on ...
(Date:2/5/2016)... NY (PRWEB) , ... February 05, 2016 , ... Love ... long-stem roses in a variety of colors, assortments and packaging. This staple for Valentine’s ... any King Kullen location. , For Valentine’s Day, not only are long-stem roses ...
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment ... new clinical and scientific initiatives have all marked the last 12 months at ... and CEO of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, MD and ... their Napa Valley office. The technique utilizes the body’s own healing abilities to ... Dr. Furnas, are part of only a select few cosmetic surgeons bringing this ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016   Bernstein Liebhard LLP ... filed in the United States District Court for the District ... class (the "Class") consisting of all persons or entities who ... "Company") (NASDAQ: INSY ) from March 3, 2015 through ... and certain of its officers with violations of the Securities ...
(Date:2/4/2016)... Feb. 4, 2016 Summary Breast cancer, ... and the most common cancer in women worldwide, accounting ... exceedingly prevalent. The number of women diagnosed with breast ... the number of deaths has declined due to earlier ... has been revolutionized in the past four decades, especially ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
Breaking Medicine Technology: